Lumagenics Welcomes New VP of Corporate Development to Help Drive Critical Growth Initiatives
Cary, NC, May 28, 2019 – Today, Lumagenics announced another key hire for the company’s executive leadership team. The company welcomes Natalie Alvarez as the VP of Corporate Development to help lead the company’s efforts to expand their technology offerings and develop financial models to support organic and inorganic corporate growth.
Natalie has a passion and track record for shepherding transformative change within both small and large organizations. Natalie started her career on Wall Street, first in Investment Banking at Morgan Stanley and then in Strategy, Corporate Development, and Investor Relations at ING U.S. (now Voya Financial). She worked alongside senior management to develop and execute financial and strategic initiatives including two initial public offerings, a continuous improvement effort, a divestiture, and a full rebranding.
Natalie pivoted to healthcare given her longstanding interest in solving challenges for healthcare providers and their patients. She went on to deliver business development and operational improvement plans for executives at top academic medical centers including Memorial Sloan Kettering Cancer Center, UCLA Health, and Emory Healthcare. Prior to joining Lumagenics, she scaled and led all client operations at Radix Health, a healthcare technology company focused on improving patient access.
“As we near commercialization, Natalie’s Investment banking exposure and expertise will be critical in the development of our business model and future inorganic growth opportunities for the company.” said C.G. Gillooly, CEO.
Lumagenics projects a late 2020 launch of their first surface disinfection device.
Lumagenics is a privately held, technology platform company located near Research Triangle Park, North Carolina. Our mission is to transform today’s current disinfection approaches by harnessing UV light to combat pathogens. For more information, visit www.lumagenics.com.